Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Impairment expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zomedica

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zomedica reports revenue growth and product advancements amidst profitability challenges

Zomedica's 2022 performance reflects revenue growth and product advancements, though challenges in profitability persist. The company's strategic focus on companion animal healthcare presents growth opportunities through innovation and market stability. Addressing expense management, stock stability, and leveraging market trends will be key for Zomedica's future success.

Zomedica reports robust Q1 earnings, eyes global equine market

Zomedica's Q1 2023 showcased strong revenue growth, particularly driven by TRUFORMA and international sales.
The company's focus on maintaining margins, expanding marketing efforts, and targeting global equine markets positions it for future success.
Challenges include the closure of the cancer assay program and operational hurdles in achieving the 70% gross margin target.
Opportunities lie in the launch of new assays, international expansion, and investor engagement beyond quarterly updates.

Zomedica reports robust Q2 earnings, eyes international expansion and product launches

Zomedica's Q2 performance reflects strong revenue growth and strategic investments for future profitability.
Despite challenges like increased OpEx and lower margins, the company is focused on long-term growth through product launches and market expansion.
Opportunities lie in international market exploration, upcoming product launches, and investor engagement strategies.

Zomedica reports record revenues, eyes global expansion amidst stock challenges

Zomedica's Q3 performance reflects strong revenue growth and strategic acquisitions, despite facing challenges like potential delisting and net losses.
The company's focus on new product launches, international expansion, and partnerships presents opportunities for future growth and market diversification.
Overall, Zomedica aims to drive towards cash flow breakeven by leveraging innovative products and maintaining a strong liquidity position.

Zomedica reports record revenues, eyes profitability through strategic growth

Zomedica's strong financial performance in Q4 2023 and full-year results, coupled with a robust cash position and strategic growth initiatives, position the company for future success.
While facing challenges related to compliance requirements and integration costs, Zomedica's focus on innovation, market expansion, and profitability goals present opportunities for sustained growth.
By balancing operational efficiency, product development, and financial discipline, Zomedica aims to drive revenue growth, enhance market presence, and deliver long-term value to shareholders.

Zomedica reports revenue growth and strong cash position in Q1

Zomedica's Q1 2024 performance showed revenue growth driven by key segments, strong cash position, and focus on operational efficiency. The company faces challenges in managing expenses and achieving aggressive revenue targets. Opportunities lie in expanding product lines, international sales, and maintaining financial strength.

Zomedica reports Q2 revenue growth amidst challenges and opportunities

Zomedica's Q2 performance showed revenue growth but with challenges in sales force and noncash charges.
Strengths include achieving milestones and expanding facilities, while opportunities lie in international expansion.
The company faces the task of managing cash burn and finding a new CFO.
Expectations for the second half of 2024 include revenue growth and operational focus.

Zomedica reports record Q3 revenue, eyes global expansion opportunities

Zomedica's Q3 2024 performance showcased revenue growth, margin strength, and cost reduction efforts, positioning the company for future profitability. Strategic international partnerships and product innovations underscore growth potential.
While challenges in achieving profitability persist, Zomedica's focus on operational efficiency and global expansion presents opportunities for sustained growth. Addressing investor inquiries and executing on strategic initiatives will be key to unlocking future value.
With a solid cash position, ongoing product enhancements, and expansion into new markets, Zomedica is poised for growth. Clear communication on financial targets, operational milestones, and strategic direction will be crucial for investor confidence and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANN ARBOR, MI / ACCESSWIRE / January 11, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced Larry Heaton, CEO, will present and host one-on-one meetings with investors at the Sidoti January Virtual Investor Conference, taking place on January 18-19, 2023. The presentation will begin at 1:00 ET on January 18 and can be accessed live here: https://sidoti.zoom.us/webinar/register/WN_B975g5uzToWfETS2CN1tmw.

Zomedica to Present at Sidoti Virtual Investor Conference January 18-19

Shares in Zomedica jumped on analyst coverage with $6.00 price target. Its buy and build strategy is highly appealing.

Zomedica: High Risk High Reward Play In Veterinary Supplies

CytomX Therapeutics

Geron

Are you using these tips for investing in penny stocks? The post How to Start Investing in Penny Stocks in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Start Investing in Penny Stocks in 2023

ANN ARBOR, MI / ACCESSWIRE / December 15, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announces an update interview with the Wall Street Analyzer, and Larry Heaton, Zomedica's Chief Executive Officer. Juan Costello, Senior Analyst with the Wall Street Analyzer, and Larry Heaton, the Chief Executive Officer for Zomedica addressed various topics related to the Company.

Zomedica CEO Interview with Wall Street Analyzer Updates Company Progress and Plans

ANN ARBOR, MI / ACCESSWIRE / November 14, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company", a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, reported consolidated financial results for the three- and nine-month periods ended September 30, 2022. Amounts are presented under accounting principles generally accepted in the United States of America ("U.S. GAAP").

Zomedica Announces Third Quarter 2022 Financial Results: $4.78 Million Revenue; 75% Gross Margin & $158.49 Million in Cash, Cash Equivalents, and Available-For-Sale Securities

ANN ARBOR, MI / ACCESSWIRE / October 18, 2022 / Zomedica Corp. (the "Company") (NYSE American:ZOM) announced today that Larry Heaton, Zomedica's Chief Executive Officer, is scheduled to provide a company overview and its prospects for growth at the LD Micro Main Event XV Conference on October 25, 2022 at the Luxe Sunset Boulevard Hotelin Bel Air, California. To access the live webcast for the presentation on October 25th at 10am PDT/1:00 pm EDT, please visit https://me22.mysequire.com/ to access the Track 2 presentation; or check Zomedica's website after the conference at https://investors.zomedica.com/events-presentations for an archived copy.

Zomedica to Present at LD Micro Main Event XV Conference

ANN ARBOR, MI / ACCESSWIRE / September 13, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering novel diagnostic and therapeutic products for companion animals, today announced the commercial launch of its newest assay - Free T4 (fT4) - for the TRUFORMA In-Clinic Biosensor Testing Platform. "The proprietary point-of-care TRUFORMA free T4 assay brings a valuable diagnostic tool into the veterinary clinic for the first time," said Larry Heaton, Zomedica's Chief Executive Officer.

Zomedica Announces Launch of Free T4 Assay for Truforma(R) Diagnostic Platform

Zomedica is a developing company providing diverse veterinary supplies for large and small animals. Zomedica's PulseVet acquisition has transformed the company.

Zomedica: Growing Veterinary Supply Company, Building Big Things On The Come

ANN ARBOR, MI / ACCESSWIRE / September 6, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for equine and companion animals, is pleased to announce that the PulseVet system has been named the Official Shock Wave Therapy of the National Cutting Horse Association. "The NCHA is delighted for this longstanding partnership with PulseVet to continue," said Jay Winborn, NCHA executive director.

Zomedica Announces Designation of PulseVet® System as the Official Shock Wave Therapy of the National Cutting Horse Association

ANN ARBOR, MI / ACCESSWIRE / August 23, 2022 / Zomedica Corp. (NYSE American:ZOM) ('Zomedica' or the 'Company'), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced that Pamela Nichols, DVM has been appointed to its Board of Directors and is joining the Audit and Governance committees. Dr. Nichols is the founder of six successful veterinary hospitals and dog boarding/daycare facilities.

Zomedica Appoints Dr. Pamela Nichols, DVM to Board of Directors

Bed Bath & Beyond

Don't jump on these bandwagons unless you're willing to lose most of your money.

2 Meme Stocks That Are Still Down 50% Since February 2021

ANN ARBOR, MI / ACCESSWIRE / August 15, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or "Company, a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, reported consolidated financial results for the three and six month periods ended June 30, 2022. Amounts are presented under accounting principles generally accepted in the United States of America ("U.S. GAAP").

Zomedica Announces Second Quarter 2022 Financial Results of $4.2 Million of Revenue; 71% Gross Margin & $186.8 Million in Cash; Revenue up 51% from 2021 Combined Revenues

Ann Arbor, Michigan--(Newsfile Corp. - August 9, 2022) - Zomedica Corp. (NYSE American: ZOM) today announced that Larry Heaton, CEO, will be attending the Q3 Virtual Investor Summit. During the presentation, Zomedica Chief Executive Officer, Larry Heaton, will highlight the Company's recent acquisitions and integration of PulseVet and the assets of Revo Squared and Assisi Animal Health, and the resulting transformational business strategy, noteworthy collaborations and partnerships, and the broader going-forward corporate vision.

Zomedica Corp. to Present at Investor Summit Group's Q3 Virtual Conference

Helbiz

Tuesday Morning Corp

Which penny stocks are you watching on August 9th? The post Hot Meme Penny Stocks to Buy Now?

Hot Meme Penny Stocks to Buy Now? 3 to Watch in August

ANN ARBOR, MI / ACCESSWIRE / July 18, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced that it had acquired substantially all the assets of Assisi Animal Health LLC ("Assisi"). Assisi has created an innovative line of targeted Pulsed Electromagnetic Field (tPEMF™) devices for companion animals that provide a safe, drug-free alternative for treating pain, inflammation, anxiety, or behavioral disorders.

Zomedica Acquires Assets of Leading tPEM(TM) Company Assisi Animal Health

ANN ARBOR, MI / ACCESSWIRE / July 7, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, is expanding its manufacturing and distribution facility in Roswell Georgia, which will significantly increase capacity for production and distribution of its products. "Our PulseVet and TRUFORMA product sales are growing, and we are adding Revo2 and VetGuardian products to the mix.

Zomedica Announces New Global Manufacturing & Distribution Center

Evofem Biosciences Inc

Uxin Ltd - ADR

Check these penny stocks out for your watchlist right now The post Best Penny Stocks to Buy Right Now? 3 to Watch  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Right Now? 3 to Watch

ZOM stock is on the rise as Zomedica acquires crucial technology that will provide veterinarians with enhanced diagnostic imaging quality. The post ZOM Stock Pops 5% as Zomedica Acquires Revo Squared appeared first on InvestorPlace.

ZOM Stock Pops 5% as Zomedica Acquires Revo Squared

ANN ARBOR, MI / ACCESSWIRE / July 6, 2022 / Zomedica Corp. (NYSE American:ZOM) ('Zomedica' or the 'Company'), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced that the acquisition of the assets of Revo Squared LLC ('Revo') was recently completed. Revo's innovative MicroView digital cytology platform will provide veterinarians with best-in-class image quality while providing the first in-clinic automated slide preparation system.

Zomedica Finalizes Acquisition of Veterinary Imaging Company Revo Squared

Enjoy Technology

Luokung Technology Corp

Check these 3 trending penny stocks out The post Trending Penny Stocks to Watch in Early July  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trending Penny Stocks to Watch in Early July

ANN ARBOR, MI / ACCESSWIRE / June 28, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for equine and companion animals, is honored to announce that the United States Equestrian Federation (USEF) has named PulseVet as the Official Shock Wave Therapy Supplier of US Equestrian Team Veterinarians. "The USEF is pleased to partner with a company that supports our efforts to improve the welfare of our horses," said Bill Moroney, CEO of US Equestrian.

Zomedica Announces Designation of PulseVet(R) System as the Official Shock Wave Therapy Supplier of the United States Equestrian Team

NeuroSense Therapeutics Ltd

Toughbuilt Industries Inc

Check these three penny stocks out right now The post Best Penny Stocks to Buy as June Ends? 3 to Watch  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy as June Ends? 3 to Watch

ANN ARBOR, MI / ACCESSWIRE / June 21, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, announced today that Greg Blair, Zomedica's Vice President of Business Development & Strategic Planning, will participate in a panel discussion and will provide a deep dive into how Zomedica's products and latest technologies are supporting veterinarians in the post-covid world at Animal Health, Nutrition & Technology Innovation USA scheduled in Boston, June 21-23, 2022. The forum provides a rare opportunity to see the newest technologies from the animal health space while networking with some of the industry's senior executives.

Zomedica to Participate in Panel Discussion at Animal Health Investment Forum

Evoke Pharma

Rigel Pharmaceuticals

What to know about trading biotech stocks in 2022 The post Biotech Penny Stocks Investing Guide appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Biotech Penny Stocks Investing Guide

Nokia

Tellurian

Which penny stocks are you watching as June comes to an end? The post Best Penny Stocks to Buy With June Halfway Done?

News for Zomedica Stock (ZOM)